Prescription Rates and Prognostic Implications of Optimally Targeted Guideline-Directed Medical Treatment in Heart Failure and Atrial Fibrillation: Insights From The MISOAC-AF Trial.
Moysidis DV, Kartas A, Samaras A, Papazoglou AS, Patsiou V, Bekiaridou A, Baroutidou A, Tsagkaris C, Karagiannidis E, Daios S, Anastasiou V, Tsalikakis D, Efthimiadis G, Ziakas A, Tzikas A, Giannakoulas G.
Moysidis DV, et al. Among authors: anastasiou v.
J Cardiovasc Pharmacol. 2023 Mar 1;81(3):203-211. doi: 10.1097/FJC.0000000000001390.
J Cardiovasc Pharmacol. 2023.
PMID: 36626410